Research Scientist

Claude Science creator alec Tarashansky joins OpenEvidence. The Anthropic engineer says he will bring the research-workflow approach he built for scientists to AI tools for doctors. Listen to article. Alec Tarashansky (@AlecTPhD), who helped lead Anthropic's Claude Science workbench, said on October 3rd that he has joined OpenEvidence to work on AI for medicine. His move takes a builder of tools for scientific research into a company focused on helping doctors find and use medical evidence. Tarashansky framed the move around a shared problem: making expert knowledge more usable without asking people to do all the information-processing work themselves. In his announcement on X, he described Claude Science as a product built so that "scientists' curiosity, not their capacity to execute" sets the limit on discovery. At OpenEvidence, he wrote, he hopes to bring that approach to doctors at the point of care. From research workflows to clinical evidence. The work Tarashansky leaves behind is a broad research environment, not a single-purpose chatbot. Anthropic introduced Claude Science on June 30th as a beta app that connects Claude to more than 60 scientific skills and data sources, can work with local or remote computing resources, and keeps code and other artifacts alongside generated analyses. Researchers can use it for tasks including literature analysis, genomics and protein-structure work. Anthropic named Tarashansky as Claude Science's lead engineer at an August 20th product event. His own description of having created the product is consistent with that public role, while Anthropic's launch materials describe a larger system and team rather than a solo build. The product's design puts provenance and review alongside automation: Claude Science says it preserves the code, environment and conversation history behind figures, and includes an agent that checks citations and calculations. Anthropic has also published examples of researchers using the workbench for tasks such as single-cell analysis and long-form literature reviews. RuntimeWire recently covered Anthropic's BootLoops project for exact calculations, another effort built around applying AI to real scientific workflows while keeping experts involved in deciding what results matter. OpenEvidence addresses a narrower but higher-stakes setting. The company's product is an AI medical-search and clinical decision-support tool for verified physicians, designed to return answers grounded in medical literature and guidance. A research environment helps scientists move from data and tools toward analysis; a clinical evidence product has to help doctors retrieve and assess information relevant to patient care. Tarashansky's post describes his interest in carrying a workflow-building approach across that divide, rather than announcing a specific new product or feature. A well-funded destination, with the job details still his to define. OpenEvidence has attracted substantial investor backing as it builds in that physician-focused market. On January 21st, the company announced a $250 million Series D at a $12 billion valuation, co-led by Thrive Capital and DST Global, according to TechCrunch's report. The round gives useful context for the scale of the business Tarashansky is joining; it does not disclose his role, compensation or remit. His prior path helps explain the combination of science and software in his work. Tarashansky spent three and a half years at Chan Zuckerberg Initiative before joining Anthropic as a software engineer on its life sciences team, he wrote in a post about that move. Earlier, he pursued bioengineering research at Stanford, where the university listed him as a Bio-X fellow working on stem-cell lineage competition in tissue. He arrived at Anthropic with experience spanning computational biology and software, a combination reflected in Claude Science's attempt to connect research tools, data and compute in one environment. The change of employer does not establish that Anthropic is backing away from science. In August, Anthropic announced discounted or free Claude seats for 10,000 scientists, and in September it announced a new life sciences research group and laboratory. Both announcements predate Tarashansky's October 3rd move and point to continued investment in the field even as a product builder takes his experience elsewhere. For OpenEvidence, the hire brings someone who has worked on a system for reducing friction across a complicated expert workflow. The question is how that experience translates into a medical product where doctors need evidence they can inspect and apply, not simply faster answers. Tarashansky's announcement states the ambition; it does not yet specify what he will build or when it will reach users. RuntimeWire, Inc. get virtually zero search traffic. Please consider sharing this story. Signal check Noise Signal Where does this story land? Drag the dial. The startup AI research and products that put safety at the frontier. 81 stories Anthropic is a public benefit corporation that conducts AI research and develops products intended to secure the benefits of AI while mitigating its risks. Its products include Claude, Claude Code, Claude Cowork, Claude Design, Claude Science, and API-accessible models including Fable, Opus, Sonnet, and Haiku. Claude is offered through Free, Pro, Max, Team, and Enterprise plans, with features including web and mobile access, code execution, projects, research, connectors, enterprise search, SSO, SCIM, audit logs, compliance APIs, and HIPAA-ready offerings. The company also provides a platform for developers, batch processing, prompt caching, and US-only inference options. Stay on the wire. Breaking startup & AI news, funding scoops, and launches as they happen. Follow @runtimewire on Threads and LinkedIn.

Sage and OpenEvidence partner to bring peer-reviewed research to clinicians at the point of care. September 30, 2026 Sage, an independent academic publisher of peer-reviewed research across the health, medical, and social sciences, and OpenEvidence, the most widely used medical AI platform among U.S. physicians, today announced a strategic partnership to bring Sage's peer-reviewed content into OpenEvidence. Under the agreement, clinicians using OpenEvidence at the point of care will be able to draw on evidence from over 300 Sage journals spanning the life and biomedical sciences, health sciences, medicine, and nursing, with direct citations back to the original articles. The volume of published medical research now far outpaces what any individual clinician can track. Studies routinely take years to move from publication into everyday practice, and much of the gap is a retrieval problem: the evidence exists, but not in a form a clinician can surface in the ninety seconds between patients. The partnership is designed to shorten that path for Sage's research. Adding Sage's portfolio expands the range of specialty literature OpenEvidence can surface and synthesize when physicians ask clinical questions, deepening the evidence available across the platform. "Sage is committed to getting research into the hands of people who need it in the most useful and meaningful way," said Bob Howard, Executive Vice President, Global Journals, at Sage. "With Sage content integrated into OpenEvidence's platform, we can extend our reach and impact and meet doctors and clinicians where they are." Sage will license a portfolio of its scientific and medical content to OpenEvidence, including journals from key societies such as American Orthopaedic Society for Sports Medicine, World Stroke Organization, American Society of Neurorehabilitation, International Headache Society, Australian Society of Anaesthetists, International Society for Cerebral Blood Flow & Metabolism, Association of Diabetes Care & Education Specialists, and International Society of Endovascular Specialists. OpenEvidence, now used by 60% of practicing U.S. physicians, gives Sage research a direct path into the clinical questions physicians are asking every day. Sage content will surface within OpenEvidence answers when clinically relevant, alongside the peer-reviewed literature already available on the platform, and every response that draws on it will cite and link back to the underlying article. "We are delighted to work with Sage to bring the clinical content they publish to the point of care," said Dr. Travis Zack, Chief Medical Officer at OpenEvidence. "Through Sage's representation of outstanding medical societies, and the recent additions of IOS Press and Mary Ann Liebert, their clinical portfolio touches all areas of medicine."

OpenEvidence raises $250M at $15B valuation. OpenEvidence has raised $250 million in a funding round led by Andreessen Horowitz and Byers Capital, confirming the OpenEvidence $250 million $15 billion valuation for the AI clinical decision-support platform. How the OpenEvidence $250 million $15 billion round was confirmed. Daniel Nadler, PhD, founder and CEO of OpenEvidence, confirmed the raise and its lead investors in a Sept. 28 email to Becker's. Forbes first reported the raise earlier in September, describing it as having closed the prior week. A rapid valuation climb. The new valuation extends a rapid climb for OpenEvidence, which reached a $12 billion valuation in January after a $250 million Series D round. Reaching $15 billion roughly eight months later, on the same $250 million raise size as the January round, reflects investor demand pushing the company's valuation up considerably faster than its capital raised. What OpenEvidence does within this $250 million $15 billion valuation context. Its AI search tool gives physicians answers grounded in peer-reviewed studies and clinical guidelines from journals including the New England Journal of Medicine and JAMA. The tool functions as a point-of-care reference, letting physicians query clinical questions and receive answers tied to established medical literature rather than open-ended AI-generated responses. Adoption and Health System integration. More than half of U.S. physicians use the platform regularly, and it is embedded into Epic workflows at health systems including New York City-based Mount Sinai Health System and Sacramento, Calif.-based Sutter Health. Embedding directly into Epic lets clinicians access OpenEvidence within their existing documentation workflow rather than switching to a separate application. OpenEvidence's broader funding history behind this $250 million $15 billion raise. Founded in 2022, OpenEvidence has raised nearly $1 billion to date as investor interest in clinical AI tools continues to accelerate. Reaching that funding total in roughly four years places among the most heavily capitalized clinical AI companies, alongside continued interest across the sector from investors backing platforms addressing physician workflow and decision support. Why this fits a broader pattern of clinical AI investment. OpenEvidence's valuation growth mirrors a broader trend of rapid, large funding rounds across clinical and biotech AI companies this year, including Enveda's recent doubling to a $2 billion valuation, suggesting investor appetite for AI platforms with demonstrated clinical adoption remains strong even as questions persist industrywide about regulatory pathways and long-term differentiation. What this OpenEvidence $250 million $15 billion raise means going forward. With more than half of U.S. physicians already using the platform regularly, OpenEvidence's next phase of growth may depend on deepening its Epic integrations across additional health systems beyond Mount Sinai and Sutter Health, building on the pattern already established with those two systems. Given the company's recent global expansion announced with Anthropic to bring free clinical AI access to roughly 100 low- and middle-income countries, this new funding may also support continued investment in that international rollout alongside its core U.S. physician platform. Why investor confidence in clinical AI search tools continues building. The scale of this valuation, now among the highest of any healthcare AI startup, also reflects investors' broader bet that AI tools directly embedded in physician workflow, rather than standalone consumer-facing products, represent the most durable path to widespread clinical adoption. Given that OpenEvidence built its reputation specifically on grounding answers in peer-reviewed literature rather than general-purpose AI responses, its continued growth may reinforce a broader industry shift toward specialized, evidence-anchored clinical AI tools as the preferred model for physician-facing applications going forward. What to watch going forward. As OpenEvidence continues scaling, industry observers will likely watch whether the company's valuation growth is matched by continued physician adoption gains, and how its Epic-embedded model competes against other health systems now building or integrating alternative AI search tools like OpenAI's ChatGPT for Healthcare. Given the pace of this OpenEvidence $250 million $15 billion valuation increase, this raise may serve as a continued bellwether for investor confidence in clinical decision-support AI as the broader healthcare AI funding environment remains highly active.